
Niklas F Boeder

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3737318/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Early Clinical Experience With the TRICENTO Bicaval Valved Stent for Treatment of Symptomatic Severe Tricuspid Regurgitation: A Multicenter Registry. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121011302.	3.9	17
2	Fiveâ€year followâ€up of patients who underwent everolimusâ€eluting bioresorbable scaffold implantation. Catheterization and Cardiovascular Interventions, 2021, 97, 56-62.	1.7	0
3	Circadian variations in pathogenesis of ST-segment elevation myocardial infarction: an optical coherence tomography study. Journal of Thrombosis and Thrombolysis, 2021, 51, 379-387.	2.1	14
4	Determinants of ST-segment elevation myocardial infarction as clinical presentation of acute coronary syndrome. Journal of Thrombosis and Thrombolysis, 2021, 51, 1026-1035.	2.1	5
5	Fusion imaging guided implantation of a Tricento transcatheter heart valve for severe tricuspid regurgitation. Catheterization and Cardiovascular Interventions, 2021, 98, E780-E784.	1.7	4
6	Predictors of scaffold failure and impact of optimized scaffold implantation technique on outcome: Results from the Germanâ€Austrian ABSORB RegIstRy. Catheterization and Cardiovascular Interventions, 2021, 98, E555-E563.	1.7	1
7	Acute Mechanical Performance of Magmaris vs. DESolve Bioresorbable Scaffolds in a Real-World Scenario. Frontiers in Cardiovascular Medicine, 2021, 8, 696287.	2.4	2
8	Coronary plaque and clinical characteristics of South Asian (Indian) patients with acute coronary syndromes: An optical coherence tomography study. International Journal of Cardiology, 2021, 343, 171-179.	1.7	2
9	Age and Phenotype of Patients With Plaque Erosion. Journal of the American Heart Association, 2021, 10, e020691.	3.7	7
10	Clinical presentation does not affect acute mechanical performance of the Novolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography. Postepy W Kardiologii Interwencyjnej, 2021, 17, 272-280.	0.2	1
11	Latest Developments in Robotic Percutaneous Coronary Intervention. Surgical Technology International, 2021, 38, 325-330.	0.2	0
12	Mitral valve leaflet repair with the new PASCAL system: early real-world data from a German multicentre experience. Clinical Research in Cardiology, 2020, 109, 549-559.	3.3	22
13	Fractional flow reserve and frequency of PCI in patients with coronary artery disease. Herz, 2020, 45, 752-758.	1.1	0
14	German Multicenter Experience With a New Leaflet-Based Transcatheter Mitral Valve Repair System for Mitral Regurgitation. JACC: Cardiovascular Interventions, 2020, 13, 2769-2778.	2.9	25
15	Long-term follow-up and predictors of target lesion failure after implantation of everolimus-eluting bioresorbable scaffolds in real-world practice. International Journal of Cardiology, 2020, 312, 42-47.	1.7	4
16	Ethnic Differences in the Pathobiology of Acute Coronary Syndromes Between Asians and Whites. American Journal of Cardiology, 2020, 125, 1757-1764.	1.6	8
17	Clinical and Laboratory Predictors for Plaque Erosion in Patients With Acute Coronary Syndromes. Journal of the American Heart Association, 2019, 8, e012322.	3.7	70
18	Incidental Finding of Strut Malapposition Is a Predictor of Late and Very Late Thrombosis in Coronary Bioresorbable Scaffolds. Journal of Clinical Medicine, 2019, 8, 580.	2.4	7

Niklas F Boeder

#	Article	IF	CITATIONS
19	Calcified Plaques in Patients WithÂAcuteÂCoronary Syndromes. JACC: Cardiovascular Interventions, 2019, 12, 531-540.	2.9	92
20	OCTâ€assessment of scaffold resorption: Analysis of strut intensity by a new resorption index for poly―l ″actic acid bioresorbable vascular scaffolds. Catheterization and Cardiovascular Interventions, 2019, 94, 928-935.	1.7	0
21	Effect of Plaque Composition, Morphology, and Burden on DESolve Novolimus-Eluting Bioresorbable Vascular Scaffold Expansion and Eccentricity — An Optical Coherence Tomography Analysis. Cardiovascular Revascularization Medicine, 2019, 20, 480-484.	0.8	4
22	A multicenter postâ€marketing evaluation of the Elixir DESolve [®] Novolimusâ€eluting bioresorbable coronary scaffold system: First results from the DESolve PMCF study. Catheterization and Cardiovascular Interventions, 2018, 92, 1021-1027.	1.7	21
23	Specific biomarkers of myocardial inflammation and remodeling processes as predictors of mortality in highâ€risk patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 481-487.	1.8	11
24	Evaluation of cystatin C and neutrophil gelatinaseâ€associated lipocalin as predictors of mortality in patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 1474-1479.	1.8	4
25	Galectinâ€3 and ST2 as predictors of therapeutic success in highâ€risk patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 1164-1169.	1.8	6
26	Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the TreatmentÂof Coronary Artery Disease. JACC: Cardiovascular Interventions, 2017, 10, 477-485.	2.9	12
27	Endocarditis after interventional repair of the mitral valve: Review of a dilemma. Cardiovascular Revascularization Medicine, 2017, 18, 141-144.	0.8	17
28	Impact of strut thickness on acute mechanical performance: A comparison study using optical coherence tomography between DESolve 150 and DESolve 100. International Journal of Cardiology, 2017, 246, 74-79.	1.7	10
29	Mechanisms of Very Late BioresorbableÂScaffold Thrombosis. Journal of the American College of Cardiology, 2017, 70, 2330-2344.	2.8	117
30	Post-dilatation after implantation of bioresorbable everolimus- and novolimus-eluting scaffolds: an observational optical coherence tomography study of acute mechanical effects. Clinical Research in Cardiology, 2017, 106, 271-279.	3.3	6
31	Thebesian veins as drainage to the ventricle: A case report. Cardiovascular Revascularization Medicine, 2017, 18, 213-214.	0.8	2
32	Bioresorbable scaffold implantation in patients with indication for oral anticoagulation: A propensity matched analysis. International Journal of Cardiology, 2017, 231, 73-77.	1.7	0
33	Outcome After Long-segment Stenting With Everolimus-eluting Bioresorbable Scaffolds Focusing on the Concept of Overlapping Implantation. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1144-1151.	0.6	1
34	Everolimus-eluting bioresorbable scaffold implantation for the treatment of bifurcation lesions — Implications from early clinical experience during daily practice. Cardiovascular Revascularization Medicine, 2016, 17, 313-317.	0.8	6
35	A new novolimus-eluting bioresorbable scaffold for large coronary arteries: an OCT study of acute mechanical performance. International Journal of Cardiology, 2016, 220, 706-710.	1.7	7
36	First-in-Man Coronary Sinus Lead Stabilization Using a Bioresorbable Vascular Scaffold System. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1518-1519.	4.8	0

#	Article	IF	CITATIONS
37	Fate of Patients With Coronary Perforation Complicating Percutaneous Coronary Intervention (from) Tj ETQq1 1	0.784314 1.6	rgBT /Over 25
	Cardiology, 2015, 116, 1363-1367.		
38	Latest Developments in Robotic Percutaneous Coronary Intervention. Surgical Technology International, 0, , .	0.2	2